What is TMCI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.26B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TMCI?

P/E (TTM) is n/a and 52-week range is $1.17 to $7.08 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TMCI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TMCI?

The company profile lists revenue (TTM) near $205M, net income (TTM) near $-5.94B, EPS (TTM) near $-0.93 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Treace Medical Concepts, Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ponte Vedra, Florida, US, 64.9M shares outstanding, ISIN US89455T1097 when available from company profile and filing metadata.

Treace Medical Concepts, Inc

$TMCI

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$3.95

+1.94%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 450 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.

Employees

450

Website

www.treace.com/

IPO

2021-04-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)